Over the past few days, Sarepta Therapeutics reminded us that in public markets, credibility is not just a nice-to-have. It is a core asset. Once lost, it is incredibly challenging to recover.
In less than 48 hours, Sarepta saw its share price rise nearly 20 percent, then plunge 36 percent, erasing hundreds of millions of dollars in value. The trigger was not a failed trial or an FDA rejection. It was a decision. The company knew that a patient had died in one of its gene therapy trials and chose not to disclose it during a major business update.
That choice to withhold rather than communicate became the story, and now, investors are both aware of the unfortunate patient death, but also, that management chose to hide it from them. For a company already under pressure from earlier safety issues, the result was a complete collapse in investor confidence.
The Setup: A Strategic Reset Missing One Critical Detail
On July 17, Sarepta announced a sweeping restructuring. The company laid off 36 percent of its workforce and shifted focus away from certain gene therapies, emphasizing RNA-based approaches instead. This was framed as a return to discipline and focus. The market initially responded with optimism.
But the announcement left out something important.
Several weeks earlier, a patient in a Phase I trial of SRP-9004, Sarepta’s gene therapy for limb-girdle muscular dystrophy, had died of acute liver failure. The company was fully aware of the incident. So were trial investigators. Yet leadership made no mention of it during the investor call or in related materials.
When the news surfaced the following day through media reports, investors and analysts reacted swiftly. The company’s explanation – that the death was not material or central to the update, which to many seems questionable at best, only made matters worse. Sarepta held a follow-up call to address the issue, but by then, trust had already unraveled.
The next day, the stock dropped 36 percent. Analysts issued downgrades. Shareholders filed lawsuits. Sarepta’s credibility, already weakened by two earlier patient deaths in its Elevidys program, took another major hit.
This Was Not About the Science
Drug development is inherently risky. Patient deaths during clinical trials, while tragic, are not unheard of. Investors understand that. So do regulators. What they cannot accept is the perception that important information is being withheld.
Sarepta’s problem was not that a patient died. It was that the company appeared to believe investors did not need to know. In a field where trust is everything, that perception is enough to spark a crisis.
This was not a scientific failure. It wasn’t just a communication failure. It was a failure to understand that for publicly traded companies, especially those in highly risky and volatile sectors like biopharma, trust and perception are mission critical intangible assets that need to be taken seriously.
Four Lessons for Every Public Company
This story could have played out differently. Sarepta’s experience offers valuable lessons for any public company navigating risk and public scrutiny.
1. Transparency is not just a legal checkbox. It is a trust decision.
Materiality under securities law is not the same as what matters to investors. A better question to ask, beyond just materiality, is whether a reasonable shareholder would consider the information important, and how might they react when in inevidably comes out. If the answer is yes, it deserves to be shared clearly and early.
2. Sentiment is fragile, especially when trust has already been damaged.
By July, Sarepta had already faced two prior deaths related to Elevidys. Confidence was strained. In that context, even unrelated safety issues needed to be acknowledged. Silence looked like evasion, not confidence.
3. The market never waits. Others will fill the silence.
Today, the conversation starts before the press release is even written. News breaks on Reddit, X, Discord, and biotech Slack groups. Influential voices can shape narratives in real time. When a company chooses not to speak, it gives up control of its story.
4. Intentions matter, but perception is the ultimate decider
Sarepta may have believed it was protecting stakeholders. But investors saw something different. They saw a company that was not upfront about a serious development. In the absence of clear messaging, the market assumed the worst.
A Market That Moves Faster Than Most Leaders Expect
I work with public companies every single day and see how often executives are surprised by market reactions. They misjudge how quickly sentiment can shift and how long the impact can last.
The tools to understand investor behavior are now, for the first time, becoming available to publicly traded companies. Issuers can monitor sentiment trends, get alerted to early warning signs, and respond more effectively. But tools only go so far. What really matters is the willingness to engage with the market honestly and early.
The companies that earn long-term investor trust are not always the ones with the flashiest announcements. They are the ones that speak clearly when it counts. They treat credibility as a key asset, not a side issue. They know that transparency builds value.
Sarepta’s science may still hold promise. But its path forward is now harder than it needed to be. Rebuilding trust takes time. It takes consistency. And it starts with leadership choosing to communicate, not conceal.
For others watching this unfold, the question is simple. Are you prepared to face your own high-pressure moment with full transparency? Or will your company learn the hard way that silence can be more damaging than the news itself?